Meeting
2018 ASCO Annual Meeting
Geographic and ethnic heterogeneity in the BRCA1/2 pre-screening population for the randomized phase III POLO study of olaparib maintenance in metastatic pancreatic cancer (mPC).
Authors
Talia Golan
Institute of Oncology, Sheba Medical Center, Ramat Gan, Israel
Talia Golan , Hedy L. Kindler , Joon Oh Park , Michele Reni , Teresa Macarulla Mercade , Pascal Hammel , Eric Van Cutsem , Dirk Arnold , Daniel Hochhauser , Gershon Y. Locker , Michael J. Hall
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Clinical Trial Registration Number
NCT02184195
Citation
J Clin Oncol 36, 2018 (suppl; abstr 4115)
DOI
10.1200/JCO.2018.36.15_suppl.4115
Abstract #
4115
Poster Bd #
304
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
POLO: A randomized phase III trial of olaparib maintenance monotherapy in patients (pts) with metastatic pancreatic cancer (mPC) who have a germline BRCA1/2 mutation (gBRCAm).
First Author: Talia Golan
Poster
2015 ASCO Annual Meeting
POLO: A randomized phase III trial of olaparib tablets in patients with metastatic pancreatic cancer (mPC) and a germline BRCA1/2 mutation (gBRCAm) who have not progressed following first-line chemotherapy.
First Author: Hedy Lee Kindler
Poster
2021 Gastrointestinal Cancers Symposium
Olaparib sensitivity observed in metastatic pancreatic cancer (mPaC) with a wide spectrum of germline BRCA1 and BRCA2 mutations (gBRCAm).
First Author: Talia Golan
Poster
2020 ASCO Virtual Scientific Program
Olaparib sensitivity observed in metastatic pancreatic cancer (mPaC) with a wide spectrum of germline BRCA1 and BRCA2 mutations (gBRCAm).
First Author: Talia Golan